PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Some net income increase while AXSM is negative at -15.96%. John Neff would see a short-term edge over the struggling competitor.
0.99%
D&A growth well above AXSM's 0.58%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Negative yoy SBC while AXSM is 1.51%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
66.71%
Less working capital growth vs. AXSM's 179.63%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth well above AXSM's 165.84%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-209.52%
Negative yoy usage while AXSM is 264.05%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
100.00%
Some yoy increase while AXSM is negative at -69.07%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
51.97%
Some CFO growth while AXSM is negative at -40.64%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Negative yoy issuance while AXSM is 25.33%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.